Domain Therapeutics creates new company to stop Parkinson’s disease progression
France-based biopharmaceutical firm Domain Therapeutics has established a new company, Mavalon Therapeutics, dedicated to develop a drug candidate to stop the progression of Parkinson’s disease.
Life sciences-focused venture capital firm Medicxi Ventures has agreed to invest up to €9m in Mavalon.
